DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
69 hedge funds and large institutions have $799M invested in DICE Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 9 closing their positions.
344% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 9
77% more funds holding
Funds holding: 39 → 69 (+30)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
1% more capital invested
Capital invested by funds: $794M → $799M (+$5.71M)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$25.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$20.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.1M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.8M |
| 2 |
O
OrbiMed
New York
|
-$14.4M |
| 3 |
Millennium Management
New York
|
-$8.91M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$6.96M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.78M |
DICE Hedge Fund Activity: Q4 2021 in Review
69 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q4 2021, worth a combined $799M — up 0.72% from $794M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new DICE positions and 9 closed out — a net gain of 31 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $25.1M. The largest seller was Fidelity Investments, cutting an estimated $16.8M.
- 69 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q4 2021, up from 39 in Q3 2021.
- Funds reported $799M of DICE Therapeutics, Inc. Common Stock stock for Q4 2021, up 0.72% quarter-over-quarter.
- 40 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of +31 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $25.1M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q4 2021 was Fidelity Investments, an estimated $16.8M sold.
Based on aggregated 13F filings for Q4 2021.